Imprimis Pharmaceuticals Inc (IMMY)

3.87
0.03 0.77
NASDAQ : Health Care
Prev Close 3.90
Open 3.94
Day Low/High 3.85 / 3.99
52 Wk Low/High 3.34 / 8.79
Volume 17.23K
Avg Volume 37.90K
Exchange NASDAQ
Shares Outstanding 13.31M
Market Cap 53.22M
EPS -1.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Clinical Study Of Imprimis Pharmaceuticals' Tri-Moxi-Vanc Dropless Therapy Formulation Show Statistically Significant Reduction In Cystoid Macular Edema In Patients Following Cataract Surgery

Clinical Study Of Imprimis Pharmaceuticals' Tri-Moxi-Vanc Dropless Therapy Formulation Show Statistically Significant Reduction In Cystoid Macular Edema In Patients Following Cataract Surgery

Study results presented at the American Society of Cataract and Refractive Surgery (ASCRS) Congress in New Orleans

Imprimis Pharmaceuticals Announces Plans To Launch IV Free™ Conscious Sedation And New Compounded Triple Drop Formulations At Leading Cataract And Refractive Surgeons Meeting

Imprimis Pharmaceuticals Announces Plans To Launch IV Free™ Conscious Sedation And New Compounded Triple Drop Formulations At Leading Cataract And Refractive Surgeons Meeting

Patent-pending MKO Melt™ sublingual sedation and anesthetic provides surgeons with a new approach for patients undergoing ophthalmic and other outpatient surgical procedures

Imprimis Pharmaceuticals Begins Dispensing Lower Cost Alternative To Thiola®

Imprimis Pharmaceuticals Begins Dispensing Lower Cost Alternative To Thiola®

New customizable compounded tiopronin delayed-release formulations may significantly reduce costs and the number of pills cystinuria patients take daily

Imprimis Pharmaceuticals Registers Its Texas Facility With The FDA As An Outsourcing Facility

Imprimis Pharmaceuticals Registers Its Texas Facility With The FDA As An Outsourcing Facility

Improved efficiencies are expected for Imprimis' Dropless Therapy®

These 5 Under-$10 Stocks Are Set to Soar Higher

These 5 Under-$10 Stocks Are Set to Soar Higher

These under-$10 stocks look poised to break out and trade higher from current levels.

These 7 Stocks Under $10 Are Set to Soar Higher

These 7 Stocks Under $10 Are Set to Soar Higher

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Imprimis Pharmaceuticals To Make A Lower Cost Compounded And Customizable Alternative To Thiola®

Imprimis Pharmaceuticals To Make A Lower Cost Compounded And Customizable Alternative To Thiola®

New patent-pending formulations expand Imprimis Cares compounded drug program

Imprimis Pharmaceuticals Announces National Account Agreement With The Cataract & Laser Institute

Imprimis Pharmaceuticals Announces National Account Agreement With The Cataract & Laser Institute

Leading provider of ophthalmic surgery adopts Imprimis' Dropless Cataract Therapy™

NVISION Eye Centers Sign National Account Agreement For Imprimis Pharmaceuticals' Ophthalmic Compounded Formulations

NVISION Eye Centers Sign National Account Agreement For Imprimis Pharmaceuticals' Ophthalmic Compounded Formulations

One of the largest LASIK and cataract surgery providers in the U.S. adopts Dropless Therapy™ injectables and LessDrops™ topical drops at its 24 U.S. centers in the Western United States

Imprimis Pharmaceuticals Announces Plans To Register Its Texas Pharmacy With The FDA As An Outsourcing Facility

Imprimis Pharmaceuticals Announces Plans To Register Its Texas Pharmacy With The FDA As An Outsourcing Facility

Planned outsourcing facility is expected to comply with Current Good Manufacturing Practices (cGMP) and register with the FDA under 503B of the Federal Food, Drug, and Cosmetic Act (FDCA)

Imprimis Pharmaceuticals Announces New Economic Study Demonstrating $8.7 Billion In Potential Cost Savings Over The Next 10 Years With The Adoption Of Dropless Therapy™

Imprimis Pharmaceuticals Announces New Economic Study Demonstrating $8.7 Billion In Potential Cost Savings Over The Next 10 Years With The Adoption Of Dropless Therapy™

Imprimis' Dropless Therapy™ provides a cost-effective alternative to expensive eye drops following cataract surgery

Imprimis Pharmaceuticals Closes The Acquisition Of The Assets Of The Largest Provider Of Compounded Sinus Medications In The U.S.

Imprimis Pharmaceuticals Closes The Acquisition Of The Assets Of The Largest Provider Of Compounded Sinus Medications In The U.S.

Asset Acquisition of Topical Apothecary Group, LLC (TAG), Aerosol Science Laboratories, Inc. (ASL) and SinuTopic, Inc. (Sinus Dynamics) represents expansion opportunity into the valuable U.S. chronic care otolaryngology market

Imprimis Pharmaceuticals Appoints Anthony J. Principi To Its Board Of Directors

Imprimis Pharmaceuticals Appoints Anthony J. Principi To Its Board Of Directors

Former Secretary of the U.S. Department of Veterans Affairs adds governmental leadership and healthcare expertise to Board

Imprimis Pharmaceuticals Signs License Agreement To Bring Proprietary Compounded Ophthalmic Formulations To Ophthalmologists In Canada

Imprimis Pharmaceuticals Signs License Agreement To Bring Proprietary Compounded Ophthalmic Formulations To Ophthalmologists In Canada

Agreement represents the Company's first international licensing relationship

Imprimis Pharmaceuticals Expands Distribution Of Its Proprietary Ophthalmic And Urologic Formulations Into Texas And Virginia

Imprimis Pharmaceuticals Expands Distribution Of Its Proprietary Ophthalmic And Urologic Formulations Into Texas And Virginia

Acquisition of company's third compounding pharmacy extends sales reach to an additional 2,000 ophthalmologists and 800 urologists